Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)
Status:
Recruiting
Trial end date:
2022-05-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of gefapixant, in improving
symptoms of cough-induced stress urinary incontinence (SUI) in adult female participants with
refractory or unexplained chronic cough. The primary hypothesis is that gefapixant is
superior to placebo in reducing the frequency of cough-induced SUI episodes over 12 weeks.